Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant durvalumab after neoadjuvant chemo-immunotherapy and surgery for resectable early-stage NSCLC
NL-OMON59914Phase 3Not yet recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Oct 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Disease-free survival in patients without pathological complete response. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59914.